Nagasaki University Graduate School of Biomedical Sciences
- Academic, tech transfer
We have developed a novel humanized anti-active IL-18 monoclonal antibody that potently neutralizes bioactive IL-18, preventing cytokine/chemokine storms. We are actively seeking strategic co-development partners to accelerate clinical development. Our initial target indication is progressive fibrosing interstitial lung disease (ILD), with polymyositis/dermatomyositis (PM/DM)-ILD as the first focus. In preclinical models, the antibody halted pulmonary fibrosis. In cynomolgus monkeys, it selectively accumulates in inflamed lung tissue and blocks cytokine storms and coagulopathy in an LPS-induced DIC model, with no toxicity at high doses. Supported by AMED (Japan Agency for Medical Research and Development), we conduct IND-enabling pharmacology and safety studies and prepare for a Phase I trial in PM/DM-ILD patients with progressive pulmonary phenotype (PPF). Our IP covers the mature IL-18-specific epitope and antibody format.
Address
Nagasaki CityJapan
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}